In thyroid cancer, with different histological patterns that include PTCs, FTCs, and ATCs, the RET-PTC, RAS, and BRAF-V600E mutations promote the activation of the NF-κB pathway in differentiated tumors, thereby inducing dedifferentiation processes and also increasing the invasiveness (Figure 1 and Table 1) [18,19,20]. Here, RET is linked to thyroid gland carcinoma.